University of Washington clinical trial pipeline

13 trials changed in the last 30 days: 2 stopped, 7 with notable changes, 4 with minor changes only.

1. Stopped

   Golimumab and Apalutamide · Castration-Resistant Prostate Cancer…Golimumab and Apalutamide · Castration-Resistant Prostate Cancer, TRAMP Study

   Trial terminated

   Also in this update: Results posted: Oct 19, 2026; Study completion date changed from estimate of Apr 14, 2027 to Apr 14, 2026

   University of Washington·Phase 2· NCT05960578· Registry history of NCT05960578 on ClinicalTrials.gov (opens the registry)

   Oct 19, 2026

2. Stopped

   Etoposide, Prednisone, Vincristine, Cyclophosphamide, and…Etoposide, Prednisone, Vincristine, Cyclophosphamide, and Doxorubicin (DA-EPOCH) With or Without Rituximab Plus Recombinant Erwinia Asparaginase (JZP458) · Newly Diagnosed Ph Negative B-Acute Lymphoblastic Leukemia or T Acute Lymphoblastic Leukemia

   Recruitment suspended

   University of Washington·Phase 2· NCT06738368· Registry history of NCT06738368 on ClinicalTrials.gov (opens the registry)

   Sep 29, 2026

3. Notable

   Polatuzumab Vedotin and Combination Chemotherapy With or Without…Polatuzumab Vedotin and Combination Chemotherapy With or Without Glofitamab · Untreated Aggressive Large B-cell Lymphoma

   Phase changed: Phase 1 → Phase 1/2

   University of Washington·Phase 1/2· NCT04231877· Registry history of NCT04231877 on ClinicalTrials.gov (opens the registry)

   Oct 2, 2026

4. Notable

   Tafasitamab and Rituximab · Newly Diagnosed Follicular Lymphoma

   Recruitment opened

   Also in this update: Start date changed from estimate of Oct 31, 2026 to Oct 9, 2026

   University of Washington·Phase 2· NCT07731789· Registry history of NCT07731789 on ClinicalTrials.gov (opens the registry)

   Oct 15, 2026

5. Notable

   [18F]FTT Positron Emission Tomography/Computed Tomography to…[18F]FTT Positron Emission Tomography/Computed Tomography to Predict Treatment Response in Patients Scheduled to Receive Gemcitabine, Cisplatin, and Durvalumab for Newly Diagnosed Cholangiocarcinoma

   Recruitment opened

   University of Washington·Phase 2· NCT07673341· Registry history of NCT07673341 on ClinicalTrials.gov (opens the registry)

   Sep 25, 2026

6. Notable

   INTERACT · Inherited and Environmental Risks Acting on Body…INTERACT · Inherited and Environmental Risks Acting on Body Weight

   Enrolling by invitation only

   University of Washington·Not applicable· NCT07430852· Registry history of NCT07430852 on ClinicalTrials.gov (opens the registry)

   Oct 2, 2026

7. Notable

   D3 · Decisions During Drinking

   Results posted: Oct 8, 2026

   University of Washington·Not applicable· NCT06978140· Registry history of NCT06978140 on ClinicalTrials.gov (opens the registry)

   Oct 8, 2026

8. Notable

   Comprehensive Self-Management Intervention · Inflammatory Bowel…Comprehensive Self-Management Intervention · Inflammatory Bowel Disease

   Results posted: Sep 28, 2026

   University of Washington·Not applicable· NCT05651542· Registry history of NCT05651542 on ClinicalTrials.gov (opens the registry)

   Sep 28, 2026

9. Notable

   EC-PC · Cancer Parenting Program for the Enhancement of the…EC-PC · Cancer Parenting Program for the Enhancement of the Quality of Life · Advanced Cancer and Their Children

   Results posted: Sep 22, 2026

   University of Washington·Not applicable· NCT05477784· Registry history of NCT05477784 on ClinicalTrials.gov (opens the registry)

   Sep 22, 2026

• Stopped: an ongoing trial was terminated, suspended or withdrawn.
• Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
• Minor: routine progress and housekeeping, such as sites added or enrollment closed.